검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Reduced Intensity Conditioning (Reduced Intensity Conditioning) Genzyme, a Sanofi Company·Hodgkin Lymphoma ORR 2% |
|---|---|
Overview Program | Reduced Intensity Conditioning |
Overview Company | Genzyme, a Sanofi Company |
Overview Modality | ADC |
Overview Target | Hodgkin Lymphoma |
Overview Indication | Hodgkin Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | CAR-T-mediated effects, whereas low-dose irradiation failed to support durable CAR-T cell engr |
MoA Biomarker | Biomarker for Post-Transplant Outcomes in Allogeneic Stem Cell Transplantation Using Post-Transplant Cyclopho |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes.. A myeloablative busulfan (Bu) and fludarabine (Flu) regimen that includes fractionating Bu and extending its delivery time results in low toxicity, permitting its use in stem cell transplantation recipients who otherwise would receive re… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 2% |
Clinical ORR | 2% |
Clinical Result source | ClinicalTrials.gov NCT00054353 |
Clinical Data Tier / Score | A · 32 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Reduced Intensity Conditioning (Reduced Intensity Conditioning) Genzyme, a Sanofi Company·Hodgkin Lymphoma ORR 2% |
|---|---|
Overview Program | Reduced Intensity Conditioning |
Overview Company | Genzyme, a Sanofi Company |
Overview Modality | ADC |
Overview Target | Hodgkin Lymphoma |
Overview Indication | Hodgkin Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | CAR-T-mediated effects, whereas low-dose irradiation failed to support durable CAR-T cell engr |
MoA Biomarker | Biomarker for Post-Transplant Outcomes in Allogeneic Stem Cell Transplantation Using Post-Transplant Cyclopho |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes.. A myeloablative busulfan (Bu) and fludarabine (Flu) regimen that includes fractionating Bu and extending its delivery time results in low toxicity, permitting its use in stem cell transplantation recipients who otherwise would receive re… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 2% |
Clinical ORR | 2% |
Clinical Result source | ClinicalTrials.gov NCT00054353 |
Clinical Data Tier / Score | A · 32 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교